There was also
a counterintuitive finding worth noting. The fittest group were more
likely to be diagnosed with prostate cancer than the least fit. This is
important, as prostate cancer risk was much higher than lung or colon
cancer in the sample.
know that obesity is linked to 9 types of cancer, some more convincingly
than others. But this week, new evidence from the World Cancer Research
Fund – an organisation with substantial expertise in cancer prevention –
has concluded that as well as these types, carrying extra weight can
also cause liver cancer.
unique—a biomarker driven, multi-drug, multi-arm, study design, using a
targeted screening approach, with state-of-the-art genomic profiling of
neoplastic cells to match patients with sub-studies testing
investigational new drugs and immunotherapies, based on their unique
"Maybe we can
shift the tumour in the direction of the therapy rather than developing
the therapy in the direction of the tumour," says Rob Ramsay from the
Peter MacCallum Cancer Centre in Melbourne, Australia.
upfront haul is particularly notable given that Aduro hasn’t yet tested a
STING drug in clinical trials. So far, Aduro has only demonstrated that
an experimental STING activator compound it’s developing called
ADU-S100 can curb tumor growth in animals.
postponements happen fairly often when questions arise and officials
feel they need more time to evaluate a medicine. The nivolumab
application could be considered again either in April or at a later
date, the spokeswoman added.
compete with Bayer's cancer-fighter Nexavar, which won approval in 2013
for treating thyroid cancer, but Eisai is also hoping to win approval
for the drug for treating other cancers such as liver, kidney, lung and
course addresses the fundamental aspects of clinical trials, such as the
selection of appropriate endpoints, statistics for clinicians, and the
use of biomarkers in clinical trials of targeted treatment modalities.
reflects rising frustration with an FDA program called expanded access,
in which people who are seriously ill can obtain a drug under
development, even though they aren’t enrolled in a clinical trial.
At a time when
few physicians thought that there was a genetic cause of breast cancer,
Parker sought information and pushed her doctors for answers. Her
perspective on oncology – as a family member, patient and advocate –
spans over 50 years.
woman was so afraid of the pain coming back,” the woman whispered to
Polina, “that she begged her relatives to carry her outside in nothing
but her underwear and lay her on the snow. ‘Lay me down and wait. And
then bring me back inside. I’ll get pneumonia and die.’”
must be looking at her biological children - Shiloh, eight, and
six-year-old twins Knox and Vivienne - and thinking, ‘when do I have The
Conversation with you?’ The conversation in which she must persuade
them to be tested when they are old enough to understand.
science communication in the United Kingdom have expressed “deep
concern” about a change to the Civil Service Code for public workers,
including researchers at government agencies. The three-sentence
addition, put into place on 16 March, requires that all contact with
media be approved in advance by the minister in charge of the relevant
Association for Cancer Research (AACR), the world's oldest and largest
professional organization dedicated to advancing cancer research and its
mission to prevent and cure cancer, is proud to be an outreach partner
for "CANCER: The Emperor of All Maladies," a film documentary presented
by Ken Burns.
denying that I love my job. But in recent years it has become plagued by
increasing, unmanageable workloads and huge administrative demands,
which often makes me question why I am still doing it.
delude ourselves, or our patients, in thinking that standard
chemotherapy is a thing of the past. Or that a few more months of life,
which is what many targeted drugs have been able to deliver on average,
is a panacea in cancer care.